Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe.
Options
BORIS DOI
Publisher DOI
PubMed ID
38770551
Description
BACKGROUND
Mantle cell lymphoma (MCL) is a type of B-cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real-world data are scarce.
METHODS
In this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP).
RESULTS
On average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow-up of 8.6 months, the mean duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented.
CONCLUSIONS
In summary, pirtobrutinib represented a safe and effective treatment option in a small real-world population.
Mantle cell lymphoma (MCL) is a type of B-cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real-world data are scarce.
METHODS
In this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP).
RESULTS
On average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow-up of 8.6 months, the mean duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented.
CONCLUSIONS
In summary, pirtobrutinib represented a safe and effective treatment option in a small real-world population.
Date of Publication
2024-05
Publication Type
Article
Subject(s)
Keyword(s)
compassionate use program mantle cell lymphoma outcomes pirtobrutinib
Language(s)
en
Contributor(s)
Aydilek, Enver | |
Wulf, Gerald | |
Schwarz, Friedrich | |
Rummel, Mathias | |
Stiefel, Olga | |
Kerkhoff, Andrea | |
Maulhardt, Markus | |
Melchardt, Thomas | |
Lenz, Georg | |
Shumilov, Evgenii |
Series
Cancer medicine
Publisher
Wiley
ISSN
2045-7634
Access(Rights)
open.access